ABMD Stock Performance, Insider Transaction and News

ABMD - ABIOMED, Inc.

Market Cap	17.18B	P/E	65.36	EPS this Y	-11.50%	Ern Qtrly Grth	86.40%
Income	266.76M	Forward P/E	60.77	EPS next Y	59.50%	50D Avg Chg	8.00%
Sales	1.07B	PEG	5.28	EPS past 5Y	11.86%	200D Avg Chg	31.00%
Dividend	N/A	Price/Book	11.18	EPS next 5Y	18.35%	52W High Chg	-
Recommedations	2.80	Quick Ratio	6.82	Shares Outstanding	45.09M	52W Low Chg	73.00%
Insider Own	2.02%	ROA	9.55%	Shares Float	44.37M	Beta	1.40
Inst Own	97.09%	ROE	18.24%	Shares Shorted/Prior	753.62K/2.08M	Price	381.02
Gross Margin	81.33%	Profit Margin	24.84%	Avg. Volume	1,703,123	Target Price	363.00
Oper. Margin	22.96%	Earnings Date	Feb 1	Volume	15,702,662	Change	0.00%

Healthcare | Medical Devices | United States

About ABIOMED, Inc.

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

ABMD Chatroom

Brent24 Posted - 2 months ago

@TJmaximus it’s worth way more than $ABMD. $ABMD barely grew for years. $SWAV just getting started and already has a 2nd company they’ve bought to launch into new indications entirely.

Brent24 Posted - 2 months ago

@TJmaximus It’s worth $500. The market just doesn’t understand yet. Any competition will be so far behind/inferior that it won’t gain traction. The next $ABMD

Pg69 Posted - 12/25/23

$ABMD pharmaceutical sonoma An acquired report estimates the new pulse treatment at 290 dollars with a projection of nearly 100,000 patients in the US and it means quadrupling turnover in 2024 great news boommm

muldoon92 Posted - 4 months ago

$SWAV feels like they’re on the M&A docket, but I’ve definitely felt this way for a long time and still no dice… $ABMD was bought at 16x revenue multiple. Impella offered more of a moat than what $SWAV has as we know others in the space are working on competing technologies. That being said, speak to any cards/vascular doc and they’ll tell you the same thing, SWAV isn’t going anywhere and will be here to stay… What type of a multiple can it command in this environment, and will it be something management accepts? Think a 250-300 offer plays out any diff this go around? $BSX $EW $MDT

ManagerofRisk Posted - 4 months ago

$ABMD Did this get bought out?

Torres87 Posted - 6 months ago

@RenHenInvestments JNJ dont have the money anymore after premium buyout of $ABMD

Quantisnow Posted - 9 months ago

$ABMD $STIM 📰 Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical https://quantisnow.com/i/4744973?utm_source=stocktwits 45 seconds delayed.

Ypestis Posted - 10 months ago

$ABMD Class 1 Recall…no bueno.

risenhoover Posted - 03/26/23

$ABMD ABMD / ABIOMED, Inc. Price Target Updated https://fintel.io/sfo/us/abmd?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$ABMD ABMD / ABIOMED, Inc. Price Target Updated https://fintel.io/sfo/us/abmd?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget